TRT on TikTok: separating real benefits from bro-science

What did @coach.agz actually say?

The claim is straightforward: starting TRT at above 25% body fat is a waste of time and dangerous. The creator says elevated body fat causes aromatase to skyrocket, drops SHBG, blunts androgen receptor activity through inflammation, and leaves men "more emotional, more bloated and more frustrated." The prescription: lose fat first, and if you can't do it without TRT, then TRT isn't the answer.

Worth flagging before anything else: this video promotes a community that discusses "the safest compounds" and "top quality vendors." That's not a wellness coaching pitch. That's a gray-market performance drug operation dressed up in optimization language. Whatever is accurate in this video exists alongside that context, and you should weigh it accordingly.

Does the science back this up?

Partially, yes. The underlying physiology is real, but the conclusion that men with obesity shouldn't access TRT is not supported by clinical evidence and, in some cases, gets it backwards.

Adipose tissue does express aromatase, and higher body fat correlates with increased conversion of testosterone to estradiol. This is well established (Hammoud et al., 2008, International Journal of Obesity). SHBG also tends to decrease with obesity and insulin resistance, which can affect free testosterone levels and hormone fluctuations. These are not invented facts.

Androgen receptor sensitivity and chronic low-grade inflammation are more complicated. The claim that inflammation "blunts antigen receptor activity" is either a slip of the tongue (he likely means androgen receptor) or a meaningful error. Chronic inflammation does impair androgen signaling in some tissues, but the evidence in humans is nuanced, not a clean on/off switch (Traish et al., 2014, Journal of Andrology).

The cortisol claim is directionally accurate. Obesity is associated with dysregulation of the HPA axis and elevated cortisol in some phenotypes, though it's not universal (Pasquali et al., 2006, European Journal of Endocrinology).

What did they get wrong (or right)?

The biggest error is framing TRT as contraindicated or pointless for men with obesity. Clinical endocrinology does not agree. Men with obesity are actually more likely to have hypogonadism, and testosterone therapy in that population has been shown to reduce fat mass, improve insulin sensitivity, and improve quality of life. The TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine), the largest cardiovascular outcome trial for TRT to date, enrolled men with a wide range of body compositions and found meaningful metabolic benefits.

The idea that a man with genuine hypogonadism should just "work harder" on sleep and nutrition before considering TRT is not standard of care. In men with true hypogonadism, lifestyle alone rarely restores testosterone to clinical normal ranges. Telling symptomatic men to delay treatment isn't cautious advice. It's harmful gatekeeping dressed as optimization wisdom.

What the creator got right: losing fat before or alongside TRT does improve outcomes. Dropping body fat reduces aromatase activity and can meaningfully improve the testosterone-to-estradiol ratio. That part is accurate and clinically relevant.

What should you actually know?

If you have symptoms of low testosterone, the answer is a blood test and a conversation with a licensed physician, not a TikTok creator's vendor community.

Men with obesity and hypogonadism are a real clinical population. They deserve evidence-based care, not a purity test about their body fat percentage. Research by Saad et al. (2017, Obesity Reviews) found that long-term testosterone therapy in hypogonadal obese men produced sustained reductions in body weight, waist circumference, and metabolic markers over several years. The engine-and-fuel analogy collapses here: testosterone therapy can actually help fix the engine, not just fuel it.

The 25% threshold presented as a hard cutoff has no established clinical basis. Endocrinologists evaluate testosterone levels, symptoms, comorbidities, and individual risk, not a single body fat number. Anyone using that figure as a definitive line is improvising, not practicing medicine.

• Aromatase activity does increase with adiposity, but the clinical response to TRT in obese hypogonadal men is still generally positive.
• No licensed prescriber sets a body fat percentage cutoff before qualifying patients for TRT.
• Vendor communities selling "compounds" outside of licensed medical supervision carry real legal and health risks.